Epidemiological and Serological Analysis of a SARS-CoV-2 Outbreak in a Nursing Home: Impact of SARS-CoV-2 Vaccination and Enhanced Neutralizing Immunity Following Breakthrough Infection

Epidemiological and Serological Analysis of a SARS-CoV-2 Outbreak in a Nursing Home: Impact of SARS-CoV-2 Vaccination and Enhanced Neutralizing Immunity Following Breakthrough Infection

<b>Background</b>: Despite a vaccination rate of 82.0% (<i>n</i> = 123/150), a SARS-CoV-2 (Alpha) outbreak with 64.7% (<i>n</i> = 97/150) confirmed infections occurred in a nursing home in Bavaria, Germany. <b>Objective</b>: the aim of this retrospecti...

Full description

Bibliographic Details
Main Authors:	Barbara I. Streibl, Heidi Lahne, Andreas Grahl, Philipp Agsten, Magdalena Bichler, Christa Büchl, Marco Damzog, Ute Eberle, Stefan Gärtner, Bernhard Hobmaier, Gabriele Margos, Martin Hoch, Sabrina Jungnick, Walter Jonas, Katharina Katz, Liane Laubert, Barbara Schutt, Cornelia Seidl, Bianca Treis, Daniel Weindl, Karen Zilch, Manfred Wildner, Bernhard Liebl, Nikolaus Ackermann, Andreas Sing, Volker Fingerle
Format:	Article
Language:	English
Published:	MDPI AG 2022-09-01
Series:	Microorganisms
Subjects:	SARS-CoV-2 Alpha variant nursing home outbreak breakthrough infection Comirnaty® COVID-19 vaccine epidemiology
Online Access:	https://www.mdpi.com/2076-2607/10/9/1809

Similar Items

Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak
by: Peter Willeit, et al.
Published: (2022-09-01)

SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines
by: Camilo C. Roa, et al.
Published: (2024-12-01)

Differences in the Concentration of Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 Recovery or Post-Vaccination
by: Andrzej Tretyn, et al.
Published: (2021-07-01)

In Vitro Rapid Antigen Test Performance with the SARS-CoV-2 Variants of Concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta)
by: Sabrina Jungnick, et al.
Published: (2021-09-01)

mRNA Vaccines against SARS-CoV-2: Advantages and Caveats
by: Miriam Echaide, et al.
Published: (2023-03-01)

Comparative Immunogenicity of COVID-19 Vaccines in a Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected Participants
by: David Peterhoff, et al.
Published: (2022-02-01)

Humoral Effect of SARS-CoV-2 mRNA vaccination with booster dose in solid tumor patients with different anticancer treatments
by: Chiara Piubelli, et al.
Published: (2023-02-01)

Factors Associated with Non-Severe Adverse Reactions after Vaccination against SARS-CoV-2: A Cohort Study of 908,869 Outpatient Vaccinations in Germany
by: Sven H. Loosen, et al.
Published: (2022-04-01)

The Influence of Booster Shot and SARS-CoV-2 Infection on the Anti-Spike Antibody Concentration One Year after the First COVID-19 Vaccine Dose Administration
by: Jakub Swadźba, et al.
Published: (2023-01-01)

Rhabdomyolysis Following Administration of Comirnaty®
by: Catarina Elias, et al.
Published: (2021-08-01)

Comparison of Post-Vaccination Response between mRNA and Vector Vaccines against SARS-CoV-2 in Terms of Humoral Response after Six Months of Observation
by: Sebastian Slomka, et al.
Published: (2023-10-01)

Systemic and Mucosal Humoral Immune Response Induced by Three Doses of the BNT162b2 SARS-CoV-2 mRNA Vaccines
by: Roberta Mancuso, et al.
Published: (2022-10-01)

SARS-CoV-2 Neutralization Capacity in Hemodialysis Patients with and without a Fifth Vaccination with the Updated Comirnaty Original/Omicron BA.4-5 Vaccine
by: Bo-Hung Liao, et al.
Published: (2024-03-01)

Vaccinating with a COVID-19 Vaccine: Experience of the Tertiary Allergology Center
by: Eglė Žilėnaitė, et al.
Published: (2022-01-01)

Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong
by: Yue Yat Harrison Cheung, et al.
Published: (2024-01-01)

A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network
by: Julia M. Neuhann, et al.
Published: (2022-10-01)

Response to three doses of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine: a retrospective study of a cohort of haemodialysis patients in France
by: Jean-François Verdier, et al.
Published: (2022-05-01)

Joint analysis of vaccination effectiveness and antiviral drug effectiveness for COVID-19: a causal inference approach
by: Yue Yat Harrison Cheung, et al.
Published: (2024-06-01)

Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate
by: Jesús Hermosilla, et al.
Published: (2023-10-01)

Intramyocardial Inflammation after COVID-19 Vaccination: An Endomyocardial Biopsy-Proven Case Series
by: Christian Baumeier, et al.
Published: (2022-06-01)

BNT162b2 COVID-19 Vaccine Safety among Healthcare Workers of a Tertiary Hospital in Italy
by: Flavia Beccia, et al.
Published: (2023-02-01)

The BNT162b2 mRNA COVID-19 Vaccine Increases the Contractile Sensitivity to Histamine and Parasympathetic Activation in a Human Ex Vivo Model of Severe Eosinophilic Asthma
by: Luigino Calzetta, et al.
Published: (2023-01-01)

Feasibility and Diagnostic Accuracy of Saliva-Based SARS-CoV-2 Screening in Educational Settings and Children Aged <12 Years
by: Martin Hoch, et al.
Published: (2021-09-01)

Pancreatic Injury after COVID-19 Vaccine—A Case Report
by: Artur Cieślewicz, et al.
Published: (2021-06-01)

Outliers Matter—Correlation between S1 IgG SARS-CoV-2 Antibodies and Neutralizing SARS-CoV-2 Antibodies
by: Berthold Hocher, et al.
Published: (2022-10-01)

Comparison between SARS-CoV and SARS-CoV 2
by: Fang Meng
Published: (2021-01-01)

Calcium Signals during SARS-CoV-2 Infection: Assessing the Potential of Emerging Therapies
by: Sascha Berlansky, et al.
Published: (2022-01-01)

Reactogenicity and Humoral Immune Response after Heterologous Vaxzevria/Comirnaty Vaccination in a Group of Individuals Vaccinated in the AOU Policlinic “G. Martino” (Messina, Italy): A Retrospective Cohort Study
by: Roberto Venuto, et al.
Published: (2022-10-01)

Benign Fasciculation Syndrome and Migraine Aura without Headache: Possible Rare Side Effects of the BNT162b2 mRNA Vaccine? A Case Report and a Potential Hypothesis
by: Grgur Salai, et al.
Published: (2022-01-01)

Analysis of spontaneous reports of suspected adverse reactions after vaccination against COVID-19 in Slovakia
by: Monika Lassanova, et al.
Published: (2023-01-01)

Morphometry of SARS-CoV and SARS-CoV-2 particles in ultrathin plastic sections of infected Vero cell cultures
by: Michael Laue, et al.
Published: (2021-02-01)

Diabetes and coronavirus infections (SARS-CoV, MERS-CoV, and SARS-CoV-2)
by: Azadeh Haghi Navand, et al.
Published: (2020-01-01)

A Review of SARS-CoV2: Compared With SARS-CoV and MERS-CoV
by: Huan Zhou, et al.
Published: (2021-12-01)

Data mining of coronavirus: SARS-CoV-2, SARS-CoV and MERS-CoV
by: Jung Eun Huh, et al.
Published: (2021-04-01)

Amyloidogenic proteins in the SARS-CoV and SARS-CoV-2 proteomes
by: Taniya Bhardwaj, et al.
Published: (2023-02-01)

The Race for ACE: Targeting Angiotensin-Converting Enzymes (ACE) in SARS-CoV-2 Infection
by: Elisabeth Schieffer, et al.
Published: (2022-05-01)

Comparative highlights on MERS-CoV, SARS-CoV-1, SARS-CoV-2, and NEO-CoV
by: Rajat Goyal, et al.
Published: (2022-09-01)

SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions
by: T.M. Abdelghany, et al.
Published: (2021-03-01)

SARS-CoV-2 and legionella co-infection
by: Caitlin A Gauvin, et al.
Published: (2023-01-01)

Differential Tropism of SARS-CoV and SARS-CoV-2 in Bat Cells
by: Susanna K.P. Lau, et al.
Published: (2020-12-01)